Literature DB >> 25918260

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

.   

Abstract

The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian characteristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline provides recommendations for the initial treatment of patients with newly diagnosed HCC.

Entities:  

Keywords:  Carcinoma, hepatocellular; Guidelines; Management

Mesh:

Year:  2015        PMID: 25918260      PMCID: PMC4413964          DOI: 10.5009/gnl14460

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  494 in total

1.  Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma.

Authors:  Shohei Komatsu; Takumi Fukumoto; Yusuke Demizu; Daisuke Miyawaki; Kazuki Terashima; Ryohei Sasaki; Yuichi Hori; Yoshio Hishikawa; Yonson Ku; Masao Murakami
Journal:  Cancer       Date:  2011-04-14       Impact factor: 6.860

2.  Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.

Authors:  Ji Eun Lee; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Young Kyoung You; Myung Ah Lee
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study.

Authors:  Jianhua Yin; Nan Li; Yifang Han; Jie Xue; Yang Deng; Jie Shi; Weixing Guo; Hongwei Zhang; Hongyang Wang; Shuqun Cheng; Guangwen Cao
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

4.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

5.  Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.

Authors:  Alyson McIntosh; Klaus D Hagspiel; Abdullah M Al-Osaimi; Patrick Northup; Stephen Caldwell; Carl Berg; J Fritz Angle; Curtis Argo; Geoffrey Weiss; Tyvin A Rich
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

6.  Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.

Authors:  Ju Hyun Shim; Joong-Won Park; Byung Ho Nam; Woo Jin Lee; Chang-Min Kim
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-25       Impact factor: 3.333

7.  Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.

Authors:  Masafumi Ikeda; Yasuaki Arai; Sang Joon Park; Yoshito Takeuchi; Hiroshi Anai; Jae Kyu Kim; Yoshitaka Inaba; Takeshi Aramaki; Se Hwan Kwon; Seiichiro Yamamoto; Takuji Okusaka
Journal:  J Vasc Interv Radiol       Date:  2013-03-07       Impact factor: 3.464

8.  Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial.

Authors:  L Huang; J Li; J Yan; J Sun; X Zhang; M Wu; Y Yan
Journal:  J Viral Hepat       Date:  2012-12-05       Impact factor: 3.728

Review 9.  Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies.

Authors:  Yun Ku Cho; Jae Kyun Kim; Mi Young Kim; Hyunchul Rhim; Joon Koo Han
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

10.  Comparison of usefulness of clinical diagnostic criteria for hepatocellular carcinoma in a hepatitis B endemic area.

Authors:  So Young Bae; Moon Seok Choi; Geum-Youn Gwak; Yong Han Paik; Joon Hyoek Lee; Kwang Cheol Koh; Seung Woon Paik; Byung Chul Yoo
Journal:  Clin Mol Hepatol       Date:  2012-06-26
View more
  86 in total

1.  Practical patterns for stereotactic body radiotherapy to hepatocellular carcinoma in Korea: a survey of the Korean Stereotactic Radiosurgery Group.

Authors:  Sun Hyun Bae; Mi-Sook Kim; Won Il Jang; Chul-Seung Kay; Woochul Kim; Eun Seog Kim; Jin Ho Kim; Jin Hee Kim; Kwang Mo Yang; Kyu Chan Lee; A Ram Chang; Sunmi Jo
Journal:  Jpn J Clin Oncol       Date:  2016-01-29       Impact factor: 3.019

2.  Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma.

Authors:  Jung Hee Kim; Dong Hyun Sinn; Kyunga Kim; Wonseok Kang; Geum-Youn Gwak; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

Review 3.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

Review 4.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 5.  Lessons learnt from pathologic imaging correlation in the liver: an historical perspective.

Authors:  Yvonne Purcell; Pauline Copin; Valérie Paradis; Valérie Vilgrain; Maxime Ronot
Journal:  Br J Radiol       Date:  2019-01-10       Impact factor: 3.039

6.  Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.

Authors:  Jong Man Kim; Choon Hyuck David Kwon; Jae-Won Joh; Heejin Yoo; Kyunga Kim; Dong Hyun Sinn; Gyu-Seong Choi; Joon Hyeok Lee
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

Review 7.  Overdiagnosis: An Understudied Issue in Hepatocellular Carcinoma Surveillance.

Authors:  Nicole E Rich; Neehar D Parikh; Amit G Singal
Journal:  Semin Liver Dis       Date:  2017-12-22       Impact factor: 6.115

Review 8.  2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations.

Authors:  Ashish Kumar; Subrat K Acharya; Shivaram P Singh; Anil Arora; Radha K Dhiman; Rakesh Aggarwal; Anil C Anand; Prashant Bhangui; Yogesh K Chawla; Siddhartha Datta Gupta; Vinod K Dixit; Ajay Duseja; Naveen Kalra; Premashish Kar; Suyash S Kulkarni; Rakesh Kumar; Manoj Kumar; Ram Madhavan; V G Mohan Prasad; Amar Mukund; Aabha Nagral; Dipanjan Panda; Shashi B Paul; Padaki N Rao; Mohamed Rela; Manoj K Sahu; Vivek A Saraswat; Samir R Shah; Praveen Sharma; Sunil Taneja; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2019-09-23

Review 9.  Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.

Authors:  Jeong Il Yu; Hee Chul Park
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 10.  Technical advances in external radiotherapy for hepatocellular carcinoma.

Authors:  Shin-Hyung Park; Jae-Chul Kim; Min Kyu Kang
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.